SIX Swiss Exchange reviews publicly listed companies included in ‘Highlights of 2024: Year in Review’ (Pages 52 to 55). While Santhera and Kuros made good progress, SIX recognizes the notable success of Basilea which, 20 years after its IPO in 2004, has reported increasingly robust profits.

Switzerland Global Enterprise’s Sirpa Tsimal talks to Leila Schwery and Michael Hübner of Johnson & Johnson about the company’s commitment to fostering global partnerships, the evolution of its manufacturing and supply chain strategies, and the critical role Switzerland plays in shaping its global capabilities.

Biotechnology applications are expanding globally into many areas beyond the pharmaceutical sector. A growing range of products meet consumer demands while contributing to sustainability and climate protection. However, the current European authorization process for these innovative products is unnecessarily burdensome and limits market access. Leading European business organizations have come tog

In the dynamic landscape of biotechnology, Switzerland stands out not only for the power of its innovation but also for its collaborative spirit. Despite the country accounting for just 0.5% of the world’s GDP and 0.1% of its population, Switzerland’s life sciences ecosystem punches well above its weight. Swiss biotech thrives by forging alliances that harmonize efforts, amplify outcomes, and